Skip to main content

Darbepoetin alfa

Generic name: darbepoetin alfa [ DAR-be-POE-e-tin-AL-fa ]
Brand names: Aranesp, Aranesp SureClick, Aranesp Albumin Free, Aranesp SingleJect
Dosage form: injectable solution (10 mcg/0.4 mL; 100 mcg/0.5 mL; 100 mcg/mL; 150 mcg/0.3 mL; 200 mcg/0.4 mL; 200 mcg/mL; 25 mcg/0.42 mL; 25 mcg/mL; 300 mcg/0.6 mL; 300 mcg/mL; 40 mcg/0.4 mL; 40 mcg/mL; 500 mcg/mL; 60 mcg/0.3 mL; 60 mcg/mL)
Drug class: Recombinant human erythropoietins

Medically reviewed by Drugs.com on Feb 16, 2024. Written by Cerner Multum.

What is darbepoetin alfa?

Darbepoetin alfa is a man-made form of a protein that helps your body produce red blood cells.

Darbepoetin alfa is used to treat anemia caused by chemotherapy or chronic kidney disease.

Darbepoetin alfa may also be used for purposes not listed in this medication guide.

Darbepoetin alfa side effects

Get emergency medical help if you have signs of an allergic reaction (hives, wheezing, difficult breathing, severe dizziness or fainting, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling).

Darbepoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use darbepoetin alfa. Seek emergency medical help if you have:

Darbepoetin alfa may cause serious side effects. Call your doctor at once if you have:

Common side effects of darbepoetin alfa may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Warnings

darbepoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. Seek emergency medical help if you have: chest pain, shortness of breath, sudden numbness or weakness, confusion, problems with vision or balance, trouble speaking or understanding, or pain or coldness in an arm or leg.

Darbepoetin alfa may also shorten remission time or survival time in some people with certain types of cancer. Talk with your doctor about the risks and benefits of using darbepoetin alfa.

Before taking this medicine

You should not use darbepoetin alfa if you are allergic to it, or if you have:

Darbepoetin alfa may shorten remission time in some people with head and neck cancer who are also being treated with radiation. Darbepoetin alfa may also shorten survival time in certain people with breast cancer, non-small cell lung cancer, head and neck cancer, cervical cancer, or lymphoid cancer. Talk with your doctor about the risks and benefits of using this medicine.

Tell your doctor if you have ever had:

Tell your doctor if you are pregnant or breastfeeding.

How should I use darbepoetin alfa?

Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose. Use the medicine exactly as directed.

Darbepoetin alfa is given every 1 to 4 weeks, depending on the condition you are treating. You may also need to take blood pressure medication. Follow your doctor's instructions very carefully.

Darbepoetin alfa is injected under the skin, or given as an infusion into a vein. A healthcare provider will give your first dose and may teach you how to properly use the medication by yourself.

Read and carefully follow any Instructions for Use provided with your medicine. You must know how to properly measure a full or partial dose of darbepoetin alfa. Ask your doctor or pharmacist if you don't understand all instructions.

Do not shake the medicine. Prepare an injection only when you are ready to give it. Do not use if the medicine has changed colors or has particles in it. Call your pharmacist for new medicine.

You may need frequent medical tests to be sure this medicine is not causing harmful effects. Your injections may be delayed based on the results of these tests.

Call your doctor if you feel weak, tired, light-headed, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to darbepoetin alfa.

If you need surgery, tell the surgeon ahead of time that you are using darbepoetin alfa.

Store in the refrigerator and protect from light. Do not freeze darbepoetin alfa, and throw away the medicine if it has become frozen.

Each vial (bottle) or prefilled syringe is for one use only. Throw it away after one use, even if there is still medicine left inside.

Use a needle and syringe only once and then place them in a puncture-proof "sharps" container. Follow state or local laws about how to dispose of this container. Keep it out of the reach of children and pets.

Darbepoetin alfa dosing information

Usual Adult Dose for Anemia Associated with Chronic Renal Failure:

Chronic Kidney Disease (CKD) Patients Not on Dialysis:
Initial dose: 0.45 mcg/kg IV or subcutaneously once every 4 weeks as appropriate

Comments:
-Initiate treatment only when hemoglobin is less than 10 g/dL, rate of hemoglobin decline indicates likelihood of requiring RBC transfusion, and reducing risk of alloimmunization and/or other RBC transfusion-related risks is a goal.

CKD Patients on Dialysis:
Initial dose: 0.45 mcg/kg IV or subcutaneously once a week or 0.75 mcg/kg once every 2 weeks as appropriate

Comments:
-Initiate treatment when hemoglobin is less than 10 g/dL.
-IV route is recommended for patients on hemodialysis.

Usual Adult Dose for Anemia Associated with Chemotherapy:

Initial dose: 2.25 mcg/kg subcutaneously once a week or 500 mcg subcutaneously once every 3 weeks

Duration of therapy: Until completion of chemotherapy course

Comments:
-Initiate treatment if hemoglobin is less than 10 g/dL and a minimum of 2 additional months of chemotherapy is planned.
-Use the lowest dose necessary to avoid RBC transfusions.

Use: Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy.

Usual Pediatric Dose for Anemia Associated with Chronic Renal Failure:

Less than 18 Years:
Initial dose:
-Chronic Kidney Disease (CKD) Patients Not on Dialysis: 0.45 mcg/kg IV or subcutaneously once a week or 0.75 mcg/kg once every 2 weeks
-CKD Patients on Dialysis: 0.45 mcg/kg IV or subcutaneously once a week

Comments: Initiate treatment when hemoglobin is less than 10 g/dL.

What happens if I miss a dose?

Call your doctor for instructions if you miss a dose of darbepoetin alfa.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while using darbepoetin alfa?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What other drugs will affect darbepoetin alfa?

Other drugs may affect darbepoetin alfa, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Popular FAQ

Jesduvroq and Aranesp are both used to raise hemoglobin levels and to treat anemia associated with chronic kidney disease (CKD). However, they differ in their active ingredients, indications, ways of working in the body, routes, frequency of administration, side effect profiles, and warnings. Neither Jesduvroq nor Aranesp has been proven to improve quality of life, tiredness (fatigue), or well-being. Continue reading

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.